Login / Signup

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.

Dominika PodkowinskiEva Orlowski-WimmerGerhard ZlabingerAndreas PollreiszAnna Sophie Mursch-EdlmayrSiegfried MariacherMichael RingMatthias Bolz
Published in: Acta ophthalmologica (2019)
The dexamethasone implant affected the aqueous cytokines and proteins MCP-1, sICAM-1, sVCAM-1 and MIG, whereas ranibizumab treatments reduced VEGF and PIGF levels. Morphological changes may diverge from cytokine changes. Results may indicate a rationale for a combination therapy for CSME using both agents, the dexamethasone implant and repeatedly administered ranibizumab injections.
Keyphrases
  • age related macular degeneration
  • diabetic retinopathy
  • high dose
  • low dose
  • soft tissue
  • optical coherence tomography
  • vascular endothelial growth factor
  • ionic liquid
  • type diabetes
  • clinical trial
  • cataract surgery